Company Product Description Indication Status
Phase I
Biodelivery Sciences International Inc., of Raleigh, N.C. Belbuca Buprenorphine buccal film Pain management Results showed its effect on respiratory drive was comparable to placebo at all doses tested
Huya Bioscience International, of San Diego HBI-3000 Multi-ion channel blocker Cardioversion of atrial fibrillation Results showed it was well-tolerated with no dose-limiting adverse events or arrhythmias observed
Sorrento Therapeutics Inc., of San Diego Resiniferatoxin Binds to TRPV1 receptors Intractable cancer pain  An interim analysis of an ongoing phase Ib study showed no dose-limiting toxicities or notable adverse events unrelated to progression of underlying disease were encountered for any of the subjects; the most common adverse event was transient post-procedural pain in 7 of 14 subjects (50%)
Phase II
Antibe Therapeutics Inc., of Toronto, ATB-346 Anti-inflammatory/analgesic agent Osteoarthritis  Last patient was enrolled in the phase IIb dose-ranging, efficacy study 
Galera Therapeutics Inc., of Malvern, Pa. Avasopasem manganese (GC-4419) Superoxide dismutase mimetic Severe oral mucositis  Results from 2-year follow-up of patients with head and neck cancer in a phase IIb trial showed tumor outcomes were maintained in both avasopasem manganese dose groups compared to placebo, and outcomes for the 90-mg dose group were comparable to placebo across all 4 measures – overall survival, progression-free survival, locoregional control and metastasis-free survival
Ironwood Pharmaceuticals Inc., of Boston IW-3718 Gastric-retentive formulation of bile acid sequestrant Refractory gastroesophageal reflux disease Phase IIb data published in Gastroenterology showed that a 1,500-mg dose given twice daily with a proton pump inhibitor (PPI) significantly reduced heartburn severity and reduced frequency of regurgitation vs. a PPI alone

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments